On October 24, 2025, Kura Oncology, Inc. announced that it received a $30 million milestone payment from its partner Kyowa Kirin under the collaboration agreement for the ziftomenib AML program. The payment was triggered by the dosing of the first patient in the company’s KOMET‑017 Phase 3 registrational trials, which evaluate ziftomenib in combination with intensive and non‑intensive chemotherapy regimens for newly diagnosed NPM1‑mutated or KMT2A‑rearranged acute myeloid leukemia.
The KOMET‑017 trials, launched on September 29, 2025, are the first menin‑inhibitor program to pursue registrational studies across both intensive and non‑intensive chemotherapy settings. The milestone payment confirms that the program has reached a critical early‑stage clinical milestone and provides additional financial support for the ongoing development of ziftomenib.
Under the collaboration agreement, Kura is eligible for up to $375 million in near‑term milestone payments. The $30 million infusion strengthens the company’s cash position and supports continued progress toward regulatory submission and potential approval of ziftomenib in relapsed/refractory NPM1‑mutant AML.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.